USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Hipple Cancer Research
City: Dayton
State: OH
Zip+4: 45439
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,011,078.00 17
SBIR Phase II $5,376,381.00 11

Award List:

IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Francis Aliosman , Principal Investigator
Award Amount: $49,960.00

DEVELOPMENT OF IMPROVED TECHNIQUES FOR THE CLONING OF HUMAN

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Francis Aliosman , Principal Investigator
Award Amount: $49,810.00

DEVELOPMENT OF IMPROVED TECHNIQUES FOR THE CLONING OF HUMAN

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Francis Aliosman , Principal Investigator
Award Amount: $245,000.00
Abstract:
The development of human tumor colony forming assays (htcfa) has opened new possibilities for basic and clinical cancer research. however, the performance of the double-layer agar technique currently used by the majority of investigators has been generally low. in this contract, we propose the… More

IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Francis Aliosman , Principal Investigator
Award Amount: $332,369.00
Abstract:
Among the major dose-limiting toxicities of currently used anticancer drugs are those affecting the bone marrow, cardiovascular system, lungs, gastrointestinal tract and the nervous system. however, hematotoxicities constitute the most common and often most significant side effect of the majority of… More

POLYPORUS UMBELLATUS: A NEW BIOLOGICAL RESPONSE MODIFIER

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: J Peter Fuhrer Phd
Award Amount: $44,000.00

POLYPORIN A: A NEW ANTI-AIDS IMMUNOREGULATORY DRUG

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The pharmacological activities of an extract of polyporus umbellatus, a mushroom indigenous to china, have been investigated extensively by the national institutes of pharmaceutical research & development. polyporin a, a polysaccharide purified from the extract, has been shown to have… More

POLYPORUS UMBELLATUS: A NEW BIOLOGICAL RESPONSE MODIFIER

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator: J Peter Fuhrer Phd
Award Amount: $500,000.00
Abstract:
The pharmacological activities of an extract of polyporus umbellatus, a mushroom indigenous to china, have been investigated extensively by the state pharmaceutical administration of china. compound 757, a polysaccharide purified from the extract, has been shown to have antitumor and… More

EFFECTS OF A BLOOD CELL GROWTH FACTOR

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $50,000.00

EFFECTS OF A BLOOD CELL GROWTH FACTOR

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $500,000.00
Abstract:
The hematopoietic activities of cordyceps sinensis (cs), a rare chinese fungus, are known. recently, cs has been shown to have adjuvant effects when administered to patients with hematologic diseases and to cancer patients during or after chemotherapy or radiotherapy. cs has been shown to have… More

IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $500,000.00
Abstract:
The clinical utility of many anticancer and anti-hiv drugs is frequently limited by their serious toxicities, myelotoxicity being the most compromising dose-limiting complication. furthermore, all preclinical drug toxicology is performed in vivo, which is often very costly and time consuming. this… More

INDOLEAMINE 2,3-DIOXYGENASE IN OPPORTUNISTIC INFECTIONS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Wei Dai
Award Amount: $50,000.00
Abstract:
Central nervous system toxoplasmosis has caused disability and death in up to 30% of patients with aids. current clinical treatment for toxoplasma infection is mainly chemotherapeutical, which is often associated with dose-related bone marrow suppression. complete remission of the infection depends… More

ADAPTION OF CAPSCAN TECHNOLOGY TO HEMATOPOIETIC ASSAYS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $47,417.00

AMINE OXIDASE-DEPLETED CELL CULTURE MEDIA FOR STEM CELLS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kunthavi Natarajan
Award Amount: $47,418.00

MONOCLONAL AND POLYCLONAL MAGAKARYOCYTE CSF ANTIBODIES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $49,965.00

A DEFINED MEGAKARYOCYTE PROGENITOR (CFU-MEG) ASSAY

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Connie L Erickson-miller
Award Amount: $49,824.00

MONOCLONAL AND POLYCLONAL MAGAKARYOCYTE CSF ANTIBODIES

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $500,000.00
Abstract:
The production of megakaryocytes from progenitor cells in the marrow can be stimulated by a lineage-specific factor-megakaryocyte colony-stimulating factor (meg-csf). the lineage-specific stimulation of megakaryocytes by meg-csf and subsequent increase in platelet number has great clinical… More

A DEFINED MEGAKARYOCYTE PROGENITOR (CFU-MEG) ASSAY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Connie L Erickson-miller
Award Amount: $500,000.00
Abstract:
One of the toxic effects of anti-cancer and anti-hiv chemotherapy is thrombocytopenia. the colony forming unit-megakaryocyte (cfu-meg) is a measure of the number of marrow progenitor cells capable of proliferating and differentiating into a megakeryocyte colony. this assay is useful in evaluating… More

ADAPTION OF CAPSCAN TECHNOLOGY TO HEMATOPOIETIC ASSAYS

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Martin J Murphy Jr
Award Amount: $500,000.00
Abstract:
The hipple cancer research corporation developed patented technology (capscan tm) for quantitating particles inside microcapillary tubes, including tumor cell colonies. hipple also pioneered microcapillary-based hematopoietic assays for human myelotoxicity testing of investigational agents.… More

Development of Human Megakaryocyte Progenitor Assay

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Connie L. Erickson-Miller
Award Amount: $69,490.00

Molecular Assay for Megakaryocyte Stimulating Factor

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Martin J. Murphy Jr.
Award Amount: $50,000.00

AMINE OXIDASE-DEPLETED CELL CULTURE MEDIA FOR STEM CELLS

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kunthavi Natarajan
Award Amount: $512,000.00
Abstract:
A family of plasma enzymes named amine oxidases contribute to a lack of survival of hematopoietic progenitor cells in vitro by oxidizing the amines released into the medium into cytotoxic and mutagenic hydrogen peroxide and aldehydes. this short-term toxicity manifests as low cloning efficiencies.… More

Development of Human Megakaryocyte Progenitor Assay

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: Connie L. Erickson-Miller
Award Amount: $540,000.00
Abstract:
With the advent of cytokine therapy, thrombocytopenia is the major dose-limiting toxicity of anti-cancer and anti-AIDS drugs. Early screening of developmental agents for toxicity to hematopoietic, particularly megakaryocytic, progenitors would allow the selection of drugs that are effective against… More

Molecular Assay for Megakaryocyte Stimulating Factor

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Martin J. Murphy Jr.
Award Amount: $747,012.00
Abstract:
Megakaryocyte colony-stimulating factor (Meg-CSF) is a lineage specific factor that specifically regulates the proliferation and differentiation of megakaryocytes from bone marrow. Meg-CSF is of significant importance in the treatment of thrombocytopenia due to diseases of a variety of etiologies,… More

HPV Oncogenic Marker Assay for Cervical Carcinomas

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sohan Gupta
Award Amount: $64,341.00
Abstract:
Cervical cancer represents the second most frequent cancer in women after breast cancer. Human papi(HPVs) are implicated as a causative agent in several human cancers, especially squamous tumors of tanogenital region, the risk being highest with HPV types 16 and 18. The carcinogenic potential of… More

Retinoic Acids and Cytokines in Hematopoiesis

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yisheng Wang
Award Amount: $99,856.00
Abstract:
This Phase I application is concerned with the secretion of G-CSF by bone marrow mononuclear cellsstimulation by a combination of retinoids and natural product extract from a Chinese fungus . Retinoto prevent and treat certain types of cancers while the FE is used in traditional Chinese medicine tof… More

Automated Image Analysis of Megakaryocyte Progenitors

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Martin Murphy
Award Amount: $100,000.00
Abstract:
The objective of this feasibility study is development of a sensitive instrument, based on image ancount megakaryocyte colonies (CFU-meg), the number of megakaryocytes per colony, megakaryocyte maturploidy. This automatic counter can be used to 1) measure the toxicity of anti-cancer drugs on… More

Indoleamine 2,3-Dioxygenase and AIDS Dementia Complex

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sohan Gupta
Award Amount: $88,997.00
Abstract:
Patients infected with human-deficiency virus (HIV)-1 resulting in the development of acquired immusyndrome (AIDS) often develop neurological disease named AIMS Dementia Complex (ADC). The underlyingADC is not clearly understood. Models proposed include a direct toxicity of HIV proteins or… More